
    
      This is a Phase 2, open-label study to explore the effect of selinexor (KPT-330) therapy in
      patients with metastatic castration-resistant prostate cancer (mCRPC). Approximately 50
      patients are planned for enrollment. Patients will receive an oral dose of selinexor on one
      of three dosing schedules.
    
  